Array Technologies, Inc. (NASDAQ:ARRY)

Tuesday, July 7, 2015 | Web News
Array is initiating a 12-patient proof-of-concept study of ARRY-797 in patients with LMNA-related dilated cardiomyopathy (DCM), a serious, genetic cardiovascular disease,...
See All Research...
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies are currently advancing. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca).

Web site: http://www.arraybiopharma.com

Last updated July 7, 2015